Eli Lilly and Company - Capital Expenditures

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Capital-Expenditures" stands at 7.04 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 12/31/2023.

Eli Lilly and Company's third quarter result of 0.2239 Billion USD for the item "Capital Expenditures" represents a decrease of -87.59 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of 0.2239 Billion USD for the item "Capital Expenditures" represents a decrease of -94.63 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of 7.04 Billion USD for the item "Capital Expenditures" represents a decrease of -35.92 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes a decrease of -14.24 percent compared to the value the year prior.
The 1 year change in percent is -14.24.
The 3 year change in percent is 156.90.
The 5 year change in percent is 362.31.
The 10 year change in percent is 359.96.

The Serie's long term average value is 2.76 Billion United States Dollars. It's latest available value, on 09/30/2025, is 155.44 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 09/30/2012, to it's latest available value, on 09/30/2025, is +769.97%.
The Serie's change in percent from it's maximum value, on 06/30/2025, to it's latest available value, on 09/30/2025, is -35.92%.